Zhang Yu, Liu Aijing, Cui Hongyu, Qi Xiaole, Liu Changjun, Zhang Yanping, Li Kai, Gao Li, Wang Xiaomei, Pan Qing, Gao Yulong
State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, 150069, People's Republic of China.
State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, 150069, People's Republic of China; Jiangsu Co-Innovation Center for the Prevention and Control of Important Animal Infectious Disease and Zoonoses, Yangzhou University, Yangzhou, 225009, People's Republic of China.
Vet Microbiol. 2022 Jan;264:109285. doi: 10.1016/j.vetmic.2021.109285. Epub 2021 Nov 17.
Hepatitis-hydropericardium syndrome (HHS) in birds is mainly caused by virulent fowl adenovirus 4 (FAdV-4). A novel genotype, hypervirulent FAdV-4, emerged in 2015 with a high mortality rate ranging from 30 % to 100 % in chickens. Vaccination is an economically feasible method to control HHS. Although there have been various reports of inactivated vaccines from virulent wild-type FAdV-4 against HHS, biosafety threats of inactivated vaccines from potential pathogenic components have been presented to the poultry industry, and safer vaccines are urgently needed. A non-pathogenic recombinant FAdV-4 strain, designated as rHN20, was generated based on the hypervirulent strain in our previous study. Here, we developed a novel inactivated oil-adjuvanted vaccine derived from rHN20 strain and evaluated its immunogenicity in specific-pathogen-free chickens. Chickens subcutaneously or intramuscularly immunized with the inactivated vaccine produced high titers of neutralizing antibodies and were protected from a lethal dose of virulent wild-type FAdV-4 challenge. Collectively, an inactivated vaccine was developed, which was capable of providing full protection for chickens against HHS, and significantly reduced the potential biosafety threats.
禽肝炎-心包积水综合征（HHS）主要由强毒禽腺病毒4型（FAdV-4）引起。2015年出现了一种新型基因型，即超强毒FAdV-4，在鸡群中的死亡率高达30%至100%。疫苗接种是控制HHS的一种经济可行的方法。尽管已有多种关于用强毒野生型FAdV-4制备的灭活疫苗预防HHS的报道，但来自潜在致病成分的灭活疫苗对家禽业存在生物安全威胁，因此迫切需要更安全的疫苗。在我们之前的研究中，基于超强毒株构建了一株非致病性重组FAdV-4毒株，命名为rHN20。在此，我们开发了一种源自rHN20毒株的新型灭活油佐剂疫苗，并评估了其在无特定病原体鸡中的免疫原性。用该灭活疫苗皮下或肌肉注射免疫的鸡产生了高滴度的中和抗体，并对致死剂量的强毒野生型FAdV-4攻击具有抵抗力。总的来说，我们开发了一种灭活疫苗，它能够为鸡提供针对HHS的完全保护，并显著降低潜在的生物安全威胁。
